Abstract
Background
End-stage renal disease patients on hemodialysis are on complex drug regimens consisting of multiple medications, many of which are administered in several doses per day. Consequently, such patients are at high risk for developing drug therapy-related problems (DTRPs). The aim of this study was to detect DTRPs in children undergoing hemodialysis and to assess and evaluate the impact of interventions by the clinical pharmacist on the clinical outcome of children undergoing hemodialysis.
Methods
Fifty hemodialysis outpatients were randomly divided into two groups (25 each): the control group and the test group. During the 9-month study period, patients in the control group received the usual medical care, and those in the test group received pharmaceutical care 3 times weekly in addition to the usual medical care.
Results
After 9 months of pharmaceutical care implementation, the test group showed a significant decline in systolic and diastolic blood pressure (p = 0.0001), serum phosphorus level (p = 0.006) and parathyroid hormone level (p = 0.001) versus their baseline values and versus the control. The serum Ca*P product level of the test group decreased (p = 0.001) after intervention versus baseline. Serum calcium level significantly increased in test group (p = 0.02) and decreased in the control group (p = 0.001) versus the respective baseline values. Satisfaction with the renal treatment significantly improved in the test group (p = 0.0001) versus the control group after 9 months of pharmaceutical care implementation based on Renal Treatment Satisfaction Questionnaire scores.
Conclusions
Pharmacist-initiated pharmaceutical care improved the satisfaction and biochemical findings of patients on hemodialysis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Harambat J, Stralen KV, Kim JJ, Tizard EJ (2012) Epidemiology of chronic kidney disease in children. Pediatr Nephrol 27:363–373
U.S. Renal Data System (USRDS) (2012) 2012 Annual Data Report (vol. 1: Atlas of chronic kidney disease in the United States; vol. 2: atlas of end-stage renal disease in the United States). USRDS Coordinating Center, Minneapolis
Stralen KJV, Tizard EJ, Verrina E, Schaefer F (2010) Demographics of pediatric renal replacement therapy in Europe: 2007 annual report of the ESPN/ERA-EDTA registry. Pediatr Nephrol 25:1379–1382
Shroff R, Ledermann S (2009) Long-term outcome of chronic dialysis in children. Pediatr Nephrol 24:463–474
Fischbach M, Edefonti A, Schroder C, Watson A (2005) Hemodialysis in children: General practical guidelines. Pediatr Nephrol 20:1054–1066
Sathvik BS, Mangasuli S, Narahari MG, Gurudev KC, Parthasarathi G (2007) Medication knowledge of hemodialysis patients and influence of clinical pharmacist-provided education on their knowledge. Indian J Med Sci 69:232–240
Ibrahim N, Wang I, Patey I, Tomlin S, Sinho M, Jani Y (2013) Drug–related problems in children with chronic kidney disease. Pediatr Nephrol 28:25–31
Cipolle RJ, Strand LM, Morley PC (1998) Pharmaceutical care practice, 2nd edn. McGraw Hill, New York
Joy MS, Dehort RM, Gilmartin C, Hachey DM, Hudson JQ, Pruchnicki M, Dirno P, Grabe DW, Sasean J, Zillich AJ (2010) Clinical pharmacist as multidisciplinary health care providers in the management of chronic kidney disease. Am J Kidney Dis 45:1105–1118
Manley HJ, Drayer DK, Muther RS (2003) Medication-related problem type and appearance rate in ambulatory hemodialysis patients. BMC Nephrol 4:10–15
Gunar S, Rosa LG (2011) Clinical pharmacy activities in chronic kidney disease and end stage renal disease patients: a systemic literature review. BMC Nephrol 12:34–40
Kaplan B, Mason NA, Shimp LA, Ascione FJ (1994) Chronic haemodialysis patients. Part II: reducing drug related problems through application of the focused drug therapy review program. Ann Pharmacother 28:320–324
Tang I, Varhnos D, Hatoum H, Lau A (1993) Effectiveness of clinical pharmacist interventions in a haemodialysis unit. Clin Ther 15:459–464
Grabe DW, Bailie GR, Eisele G (1997) Evaluation of drug related problems in an outpatient haemodialysis unit and the impact of a clinical pharmacist. Clin Nephrol 47:117–121
Barendse SM, Speight J, Bradely C (2005) The renal treatment satisfaction questionnaire (RTSQ): a measure of satisfaction with treatment for chronic kidney failure. Am J Kidney Dis 45:572–579
Chisholm MA, Mulloy LL, Jagadeesan M (2002) Effect of clinical pharmacy services on the blood pressure of African American renal transplant patients. Ethn Dis 12:392–397
Leung WY, So WY, Tong PC (2005) Effect of structured care by a pharmacist diabetes specialist team in patients with type 2 diabetic nephropathy. Am J Med 118:1414–1418
Yokum D, Glass G, Cheung CF (2008) Evaluation of phosphate management protocol to achieve optimum serum phosphate levels in hemodialysis patients. J Ren Nutr 18:521–529
Financial support
None.
Conflict of interest
None
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
El Borolossy, R., El Wakeel, L., El Hakim, I. et al. Implementation of clinical pharmacy services in a pediatric dialysis unit. Pediatr Nephrol 29, 1259–1264 (2014). https://doi.org/10.1007/s00467-014-2760-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-014-2760-4